AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11038481 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational resources
Number of subjects: 0
Study 11038481 — intervention group
Group type: EXPERIMENTAL
Intervention: Support organizations
Number of subjects: 0
Study 11038481 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional services
Number of subjects: 0
Study 8898646 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat amylase inhibitor preparation (3.0 mg/mL)
Number of subjects: 3
Study 8898646 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat amylase inhibitor preparation (4.5 mg/mL)
Number of subjects: 3
Study 8898646 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat amylase inhibitor preparation (6.0 mg/mL)
Number of subjects: 3
Study 1853700 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 10 micrograms/kg (A10)
Number of subjects: 68
Study 1853700 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 25 micrograms/kg (A25)
Number of subjects: 68
Study 1853700 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 50 micrograms/kg (A50)
Number of subjects: 68
Study 1853700 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 68
Study 7049504 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 400 mg once daily (at 9:00 P.M.)
Number of subjects: 12
Study 7049504 — intervention group
Group type: COMPARATOR
Intervention: Sulindac 200 mg b.i.d. (at 9:00 A.M. and 9:00 P.M.)
Number of subjects: 12
Study 7049504 — intervention group
Group type: COMPARATOR
Intervention: Sulindac 200 mg b.i.d.
Number of subjects: 12
Study 7049504 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 400 mg once daily
Number of subjects: 12
Study 31861788 — intervention group
Group type: EXPERIMENTAL
Intervention: six-month structural and social food store intervention
Number of subjects: 16
Study 31861788 — intervention group
Group type: COMPARATOR
Intervention: wait-list control condition
Number of subjects: 16
Study 28299543 — intervention group
Group type: EXPERIMENTAL
Intervention: Short message intervention (SMS)
Number of subjects: 210
Study 28299543 — intervention group
Group type: COMPARATOR
Intervention: Group training
Number of subjects: 210
Study 27392615 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C-acetate PET/CT positive scan
Number of subjects: 121
Study 27392615 — intervention group
Group type: COMPARATOR
Intervention: 11C-acetate PET/CT negative scan
Number of subjects: 121
Study 27392615 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest SUVmax
Number of subjects: 121
Study 27392615 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lipogenic activity (TLA)
Number of subjects: 121
Study 27392615 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of bone metastases
Number of subjects: 121
Study 27392615 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertile of TLA
Number of subjects: 121
Study 27392615 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Gleason score
Number of subjects: 121
Study 24699132 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent preload (low-energy/liquid; high-energy/semi-solid)
Number of subjects: 27
Study 24699132 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent preload (low-energy/semi-solid; high-energy/liquid)
Number of subjects: 27
Study 24699132 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to food
Number of subjects: 27
Study 23114379 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (12-week structured exercise and nutrition program)
Number of subjects: 100
Study 23114379 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 100
Study 20504163 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltalog10(IQ12)
Number of subjects: 17
Study 20504163 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltalog10(IQ24)
Number of subjects: 17
Study 20504163 — intervention group
Group type: EXPERIMENTAL
Intervention: DeltaIIP12
Number of subjects: 17
Study 20504163 — intervention group
Group type: EXPERIMENTAL
Intervention: DeltaIIP24
Number of subjects: 17
Study 20504163 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltalog10(IQmax)
Number of subjects: 17
Study 20504163 — intervention group
Group type: EXPERIMENTAL
Intervention: DeltaIIPmax
Number of subjects: 17
Study 17997623 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 28
Study 17997623 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (age-appropriate movie)
Number of subjects: 28
Study 15889697 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (0.625 mg) IV infusion
Number of subjects: 15
Study 15889697 — intervention group
Group type: COMPARATOR
Intervention: No ACE inhibition (control)
Number of subjects: 15
Study 12171952 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-H pylori treatment (omeprazole 20 mg + clarithromycin 500 mg + amoxicillin 1 g, all twice daily for one week followed by placebo for four weeks)
Number of subjects: 660
Study 12171952 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-H pylori treatment (omeprazole 20 mg + clarithromycin 500 mg + amoxicillin 1 g, all twice daily for one week followed by omeprazole 20 mg once daily for four weeks)
Number of subjects: 660
Study 12171952 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily for five weeks
Number of subjects: 660
Study 12171952 — intervention group
Group type: COMPARATOR
Intervention: Placebo for five weeks
Number of subjects: 660
Study 9570242 — intervention group
Group type: EXPERIMENTAL
Intervention: De Nol 120 mg q.i.d., clarithromycin 250 mg b.i.d. and metronidazole 250 mg q.i.d. for 2 weeks
Number of subjects: 129
Study 9570242 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg b.i.d., clarithromycin 250 mg b.i.d. and metronidazole 250 mg q.i.d. for 2 weeks
Number of subjects: 129
Study 9570242 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg b.i.d., clarithromycin 250 mg b.i.d. and metronidazole 250 mg q.i.d. for 1 week
Number of subjects: 129
Study 7664546 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP571 0.1 mg/kg
Number of subjects: 42
Study 7664546 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP571 0.3 mg/kg
Number of subjects: 42
Study 7664546 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP571 1.0 mg/kg
Number of subjects: 42
Study 7664546 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP571 3.0 mg/kg
Number of subjects: 42
Study 7664546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 2750502 — intervention group
Group type: EXPERIMENTAL
Intervention: von Bahr screws
Number of subjects: 214
Study 2750502 — intervention group
Group type: EXPERIMENTAL
Intervention: Gouffon screws
Number of subjects: 214
Study 2750502 — intervention group
Group type: COMPARATOR
Intervention: Hessel pins
Number of subjects: 214
Study 831465 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of vaccine (VV)
Number of subjects: 143
Study 831465 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of vaccine followed by placebo (VP)
Number of subjects: 143
Study 831465 — intervention group
Group type: COMPARATOR
Intervention: Two doses of placebo (PP)
Number of subjects: 143
Study 831465 — intervention group
Group type: EXPERIMENTAL
Intervention: One or two doses of the vaccine
Number of subjects: 143
Study 30618324 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 52
Study 30618324 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 52
Study 28678121 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in the U.S.
Number of subjects: 2447
Study 28678121 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 2447
Study 28678121 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 2447
Study 28678121 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk alcohol consumption
Number of subjects: 2447
Study 28678121 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <30 years
Number of subjects: 2447
Study 28678121 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained polytrauma
Number of subjects: 2447
Study 28678121 — intervention group
Group type: EXPERIMENTAL
Intervention: Gustilo-Anderson type-IIIA, B, or C fracture
Number of subjects: 2447
Study 26218826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryolipolysis treatment (60-minute cycle followed by a 2-minute massage, then a second 60-minute cycle with 50% treatment area overlap)
Number of subjects: 21
Study 26218826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryolipolysis treatment
Number of subjects: 21
Study 23150149 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT2 genotype-guided treatment (PGx-treatment: 7.5 mg/kg for rapid acetylators, 5 mg/kg for intermediate acetylators, 2.5 mg/kg for slow acetylators)
Number of subjects: 172
Study 23150149 — intervention group
Group type: COMPARATOR
Intervention: Conventional standard treatment (STD-treatment: approx. 5 mg/kg of isoniazid for all)
Number of subjects: 172
Study 21570335 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Massage (TM)
Number of subjects: 16
Study 19202343 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine powder (0.1%)
Number of subjects: 669
Study 19202343 — intervention group
Group type: COMPARATOR
Intervention: Dry cord care (DC)
Number of subjects: 669
Study 16669547 — intervention group
Group type: EXPERIMENTAL
Intervention: Prima Difesa (2 puffs per nostril, 4 times a day for 15 days) in Group A and B
Number of subjects: 80
Study 16669547 — intervention group
Group type: COMPARATOR
Intervention: Prima Difesa (1 administration) in Group C
Number of subjects: 80
Study 12897580 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% QD added to pre-existing therapy (group A)
Number of subjects: 136
Study 12897580 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost alone (group B)
Number of subjects: 136
Study 11106218 — intervention group
Group type: COMPARATOR
Intervention: 5-mg nicotine patch (placebo)
Number of subjects: 446
Study 11106218 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-mg nicotine patch
Number of subjects: 446
Study 11106218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhaler
Number of subjects: 446
Study 11106218 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-mg nicotine patch plus nicotine inhaler
Number of subjects: 446
Study 8975347 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacain Hydrochloride alone
Number of subjects: 2
Study 8975347 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacain Hydrochloride with 20 mg of Triamcinolone Hexaacetonide
Number of subjects: 2
Study 1582237 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.2 mg/kg intravenously) with flumazenil (0.1 to 0.2 mg intravenously)
Number of subjects: 100
Study 1582237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.002 mg/kg intramuscularly)
Number of subjects: 100
Study 1582237 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide and oxygen
Number of subjects: 100
Study 1582237 — intervention group
Group type: COMPARATOR
Intervention: Oxygen only
Number of subjects: 100
Study 3902677 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotoxine mesilate (DHT)
Number of subjects: 28
Study 3902677 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (CLO)
Number of subjects: 28
Study 31790343 — intervention group
Group type: COMPARATOR
Intervention: Neuropsychological Assessment Battery, Screening Module (S-NAB) administered to the S-mTBI group with symptom and test coaching to simulate impairment.
Number of subjects: 72
Study 31790343 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model using seven raw scores from S-ATT and S-EXE subtests.
Number of subjects: 72
Study 31790343 — intervention group
Group type: EXPERIMENTAL
Intervention: Two PVT formulas derived from logistic regression results.
Number of subjects: 72
Study 30950970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone (DEX) implant (0.7 mg)
Number of subjects: 62
Study 30950970 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept (2 mg, 3 monthly injections as loading phase)
Number of subjects: 62
Study 30005098 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural ingredient‐based moisturizing cream
Number of subjects: 32
Study 30005098 — intervention group
Group type: COMPARATOR
Intervention: Colloidal oatmeal moisturizing cream
Number of subjects: 32
Study 26254019 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan plus standard medical treatment
Number of subjects: 1145
Study 26254019 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment alone
Number of subjects: 1145
Study 24861549 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient clinic follow-up every two months for 6 months with screening and targeted intervention
Number of subjects: 204
Study 24861549 — intervention group
Group type: COMPARATOR
Intervention: Usual care by physician
Number of subjects: 204
Study 22617632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) administered in groups of six patients during 12 weekly sessions (n=25)
Number of subjects: 43
Study 22617632 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (n=18)
Number of subjects: 43
Study 22617632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 43
Study 20151341 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine 40 mg followed by propofol 2 mg.kg(‐1) (Group 2PL; n = 30)
Number of subjects: 90
Study 20151341 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3 mg.kg(‐1) (Group 3P; n = 30)
Number of subjects: 90
Study 20151341 — intervention group
Group type: COMPARATOR
Intervention: Propofol 2 mg.kg(‐1) (Group 2P; n = 30)
Number of subjects: 90
Study 20151341 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3 mg.kg(‐1) (Group 3P)
Number of subjects: 90
Study 20151341 — intervention group
Group type: COMPARATOR
Intervention: Propofol 2 mg.kg(‐1) (Group 2P)
Number of subjects: 90
Study 20151341 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine 40 mg followed by propofol 2 mg.kg(‐1) (Group 2PL)
Number of subjects: 90
Study 19140507 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with enalapril and prolonged-release verapamil
Number of subjects: 0
Study 19140507 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with enalapril and moxonidine
Number of subjects: 0
Study 19140507 — intervention group
Group type: COMPARATOR
Intervention: Enalapril monotherapy
Number of subjects: 0
Study 15179690 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride pretreatment for 7 to 14 days before TURP
Number of subjects: 80
Study 15179690 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 80
Study 15179690 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride pretreatment
Number of subjects: 80
Study 11113797 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of ibuprofen taken orally 1 hour before separator placement
Number of subjects: 63
Study 11113797 — intervention group
Group type: COMPARATOR
Intervention: 400 mg of ibuprofen taken orally immediately after separator placement
Number of subjects: 63
Study 11113797 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo taken orally 1 hour before separator placement and again immediately after the appointment
Number of subjects: 63
Study 9340476 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 0
Study 9340476 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 8336583 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous daily regimen of 0.3 mg CEE and one of three low-dose progestogens (medroxyprogesterone acetate 2.5 mg, levonorgestrel 30 micrograms or norethisterone 350 micrograms)
Number of subjects: 75
Study 8336583 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous daily regimen of 0.3 mg CEE and one of three low-dose progestogens
Number of subjects: 75
Study 8336583 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone therapy
Number of subjects: 75
Study 3013566 — intervention group
Group type: EXPERIMENTAL
Intervention: sulbactam/ampicillin
Number of subjects: 39
Study 3013566 — intervention group
Group type: COMPARATOR
Intervention: metronidazole/gentamicin
Number of subjects: 39
Study 30113643 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedestrian training program focusing on where to cross (n=44)
Number of subjects: 130
Study 30113643 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedestrian training program focusing on how to cross safely (n=43)
Number of subjects: 130
Study 30113643 — intervention group
Group type: COMPARATOR
Intervention: Control group (video game, n=22 for where to cross, n=21 for how to cross)
Number of subjects: 130
Study 27375972 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc (R)
Number of subjects: 137
Study 27375972 — intervention group
Group type: COMPARATOR
Intervention: Hand instrumentation (H)
Number of subjects: 137
Study 25033717 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal intercourse at least twice a week
Number of subjects: 123
Study 25033717 — intervention group
Group type: COMPARATOR
Intervention: Abstinence (control group)
Number of subjects: 123
Study 22490809 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway (CP) for etiological diagnosis of acute biliary pancreatitis
Number of subjects: 2216
Study 22490809 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard methods)
Number of subjects: 2216
Study 22490809 — intervention group
Group type: EXPERIMENTAL
Intervention: CP group
Number of subjects: 2216
Study 19703096 — intervention group
Group type: EXPERIMENTAL
Intervention: FearNot! intervention
Number of subjects: 1129
Study 18506512 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral PEMF treatment (n = 14)
Number of subjects: 42
Study 18506512 — intervention group
Group type: COMPARATOR
Intervention: Bilateral sham devices (n = 14)
Number of subjects: 42
Study 18506512 — intervention group
Group type: EXPERIMENTAL
Intervention: One breast with active device and one with sham device (n = 14)
Number of subjects: 42
Study 18506512 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative analgesic medication use
Number of subjects: 42
Study 16170233 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg in experiments 1 and 3; 150 mg in experiment 2)
Number of subjects: 68
Study 16170233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 16170233 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine deprivation state
Number of subjects: 68
Study 12544035 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc 50 mg daily
Number of subjects: 41
Study 12544035 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill containing starch
Number of subjects: 41
Study 10857888 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: three 8-mg doses of ondansetron IV at 4-hour intervals plus dexamethasone 20 mg IV from the start of chemotherapy followed by dexamethasone 5 mg IV every 12 hours.
Number of subjects: 275
Study 10857888 — intervention group
Group type: COMPARATOR
Intervention: Arm B: three 8-mg doses of ondansetron IV at 24-hour intervals plus dexamethasone 20 mg IV from the start of chemotherapy followed by dexamethasone 5 mg IV every 12 hours.
Number of subjects: 275
Study 10857888 — intervention group
Group type: COMPARATOR
Intervention: Arm A and Arm B (comparison of dosing intervals).
Number of subjects: 275
Study 8645590 — intervention group
Group type: EXPERIMENTAL
Intervention: Women attending the family history clinic and participating in the Tamoxifen Prevention Trial
Number of subjects: 186
Study 8645590 — intervention group
Group type: COMPARATOR
Intervention: Women not attending any specialist clinic (NBSP)
Number of subjects: 186
Study 1512162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial irradiation, 24 Gy and i.t. MTX 10 mg/m2, 6 doses (RT group)
Number of subjects: 54
Study 1512162 — intervention group
Group type: EXPERIMENTAL
Intervention: i.t. Ara‐C 30 mg/m2 and i.t. MTX 10 mg/m2, 10 doses (ChT group)
Number of subjects: 54
Study 1512162 — intervention group
Group type: COMPARATOR
Intervention: Control group (Siblings, Sb)
Number of subjects: 54
Study 1512162 — intervention group
Group type: COMPARATOR
Intervention: Control group (Solid Tumors, ST)
Number of subjects: 54
Study 6391073 — intervention group
Group type: EXPERIMENTAL
Intervention: One-session laser trabeculoplasty
Number of subjects: 77
Study 6391073 — intervention group
Group type: COMPARATOR
Intervention: Two-session laser trabeculoplasty
Number of subjects: 77
Study 30526261 — intervention group
Group type: EXPERIMENTAL
Intervention: Graston Technique® (GT)
Number of subjects: 26
Study 30526261 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐myofascial release (SMR)
Number of subjects: 26
Study 30526261 — intervention group
Group type: COMPARATOR
Intervention: Both GT and SMR
Number of subjects: 26
Study 30549358 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent cetuximab plus docetaxel
Number of subjects: 0
Study 30549358 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30035825 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 516
Study 30035825 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole
Number of subjects: 516
Study 30035825 — intervention group
Group type: EXPERIMENTAL
Intervention: Possible IMD
Number of subjects: 516
Study 30035825 — intervention group
Group type: COMPARATOR
Intervention: Proven/probable IMD
Number of subjects: 516
Study 26493812 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate 1 g/day
Number of subjects: 41
Study 26493812 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no calcium)
Number of subjects: 41
Study 24507221 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored training for GPs based on qualitative research findings with focus groups
Number of subjects: 0
Study 24507221 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22030802 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen uptake efficiency plateau (OUEP) during cardiopulmonary exercise testing (CPET)
Number of subjects: 508
Study 22030802 — intervention group
Group type: EXPERIMENTAL
Intervention: OUEP combined with oscillatory breathing
Number of subjects: 508
Study 22030802 — intervention group
Group type: COMPARATOR
Intervention: Other resting or exercise parameters
Number of subjects: 508